Literature DB >> 19472039

Defective solubilization of immune complexes and activation of the complement system in patients with pulmonary tuberculosis.

P Senbagavalli1, S T Geetha, P Venkatesan, V D Ramanathan.   

Abstract

INTRODUCTION: Association between inherited deficiencies of the complement components and immune complex disease indicates the importance of the complement system in the handling of circulating immune complexes. High levels of circulating immune complexes are seen in pulmonary tuberculosis. This study is, therefore, aimed to look at the concentration of circulating immune complexes, the status of complement-mediated immune complex handling, and the extent of complement activation in untreated pulmonary tuberculosis compared to treated pulmonary tuberculosis patients and healthy controls.
RESULTS: High immune complex levels, decreased complement-mediated solubilization, and increased activation of the complement system were observed in untreated tuberculosis patients.
CONCLUSIONS: The results obtained from the present study suggest that complement mediated solubilization is less in patients with tuberculosis, and this defective solubilization is likely to take part in a vicious cycle involving immune complex deposition and complement activation and, thus, may lead to disease progression depending on the nature of the defect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19472039     DOI: 10.1007/s10875-009-9301-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  16 in total

1.  Persistent reduced solubilization of immune complexes in lepromatous leprosy patients with reactions.

Authors:  V D Ramanathan; P Tyagi; U Ramanathan; K Katoch; U Sengupta; G Ramu
Journal:  Int J Lepr Other Mycobact Dis       Date:  1991-03

2.  A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions.

Authors:  V D Ramanathan; P Thyagi; U Ramanathan; K Katoch; G Ramu
Journal:  Indian J Lepr       Date:  1998 Apr-Jun

3.  Guinea pigs with inherited deficiencies of complement components C2 or C4 have characteristics of immune complex disease.

Authors:  E C Böttger; T Hoffmann; U Hadding; D Bitter-Suermann
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

4.  Activation of complement by circulating immune complexes isolated from leprosy patients.

Authors:  P Tyagi; V D Ramanathan; B K Girdhar; K Katoch; A S Bhatia; U Sengupta
Journal:  Int J Lepr Other Mycobact Dis       Date:  1990-03

5.  Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon.

Authors:  S N Wemambu; J L Turk; M F Waters; R J Rees
Journal:  Lancet       Date:  1969-11-01       Impact factor: 79.321

6.  Reduced complement-mediated immune complex solubilization in leprosy patients.

Authors:  V D Ramanathan; P Sharma; G Ramu; U Sengupta
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

7.  Isolation and analysis of circulating immune complexes in leprosy.

Authors:  V D Ramanathan; O Parkash; G Ramu; D Parker; J Curtis; U Sengupta; J L Turk
Journal:  Clin Immunol Immunopathol       Date:  1984-09

8.  The purification and identification of circulating immune complexes in tuberculosis.

Authors:  J J May; J Katilus; P M Henson; R B Dreisin
Journal:  Am Rev Respir Dis       Date:  1983-11

9.  Inhibition of immune precipitation by complement.

Authors:  J A Schifferli; S R Bartolotti; D K Peters
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

10.  Circulating immune complexes in coccidioidomycosis. Detection and characterization.

Authors:  S Yoshinoya; R A Cox; R M Pope
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

View more
  1 in total

1.  Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis.

Authors:  Jeroen Maertzdorf; Martin Ota; Dirk Repsilber; Hans J Mollenkopf; January Weiner; Philip C Hill; Stefan H E Kaufmann
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.